Protara Therapeutics, Inc.
Protara Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Next quarterly earnings (projected) on November 10, 2026, a projected date rather than a confirmed one. There are 5 upcoming events on record.
Cash runway is approximately 20 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 10, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| December 15, 2026 | Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age | Trial Milestone | Phase 2 |
| March 15, 2028 | Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support | Trial Milestone | Phase 2/Phase 3 |
| April 15, 2028 | Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer | Trial Milestone | Phase 3 |
| October 15, 2031 | Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer | Trial Milestone | Phase 2 |
Track TARA alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open TARA in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.